Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015000LC2
Mon, 28.04.2025
Mainz BioMed N.V.
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
BERKELEY, US – MAINZ, Germany – April 28, 2025 — Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the firs [ … ]
Tue, 01.04.2025
Mainz BioMed N.V.
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe
Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus
Strategic partnerships with industry leaders mark ke [ … ]
Thu, 27.03.2025
Mainz BioMed N.V.
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples
Study is on Track to Report Top-Line Results in Fourth Quarter 2025
BERKELEY, US – MAINZ, Germany – Marc [ … ]
Thu, 13.03.2025
Mainz BioMed N.V.
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples
Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfol [ … ]
Mon, 03.03.2025
Mainz BioMed N.V.
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
BERKELEY, US and MAINZ, Germany – March 3, 2025 - Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is proud to support Colorectal Cancer Awarenes [ … ]
Thu, 20.02.2025
Mainz BioMed N.V.
Mainz Biomed Expands into Switzerland with labor team w
Partnership to Launch DNA-Based Colorectal Cancer Screening Test
BERKELEY, US – MAINZ, Germany – February 20, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a [ … ]
Tue, 11.02.2025
Mainz BioMed N.V.
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness MonthUpdated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany
BERKELEY, US and MAINZ, Germany – February 11, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genet [ … ]
Mon, 27.01.2025
Mainz BioMed N.V.
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
BERKELEY, US – MAINZ, Germany – January 27, 2025 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that on January 23, 2025, the Company receive [ … ]
Tue, 21.01.2025
Mainz BioMed N.V.
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients
Multi-center study expected to complete enrollment in the second [ … ]